4D Molecular 2025 Q3 Earnings Revenue Surges 2900% as Losses Widen 29.7%

, . While the CEO projected sequential revenue growth and non-GAAP EPS improvements for 2026, .

Revenue

, .

Earnings/Net Income

, . , , underscoring persistent financial challenges.

Price Action

, .

Post-Earnings Price Action Review

; INSERT

HERE (same line) THEN ADD

The stock’s post-earnings performance reflects mixed investor sentiment. While daily and monthly gains suggest optimism about future milestones, the weekly decline highlights concerns over widening losses. , citing extended cash runway through 2028, .

CEO Commentary

CEO John A. Carter emphasized advancing molecular imaging agents and addressing manufacturing challenges, while expressing cautious optimism for 2026 due to late-stage trial progress and global partnerships.

Guidance

The company expects sequential revenue growth in Q4 2025 and non-GAAP EPS improvements in 2026, though no specific targets were provided. Capital expenditures will focus on facility upgrades to support long-term production.

Additional News

, . , . , with a Phase I update expected by year-end.

The partnership with Otsuka and recent capital raise position 4D Molecular to advance pivotal trials while navigating ongoing R&D costs. Analysts remain cautiously optimistic, balancing near-term losses with long-term therapeutic potential.